Merck & Co. Inc. (MRK) Financial News - Novartis has no need to buy Intercell-source
Merck & Co. Inc. (MRK)
Novartis has no need to buy Intercell-source
2011-07-19 06:24:52
Keywords: Ben Hirschler
Quote: The rationale for the
strategic partnership with Intercell was to gain access to
innovation in vaccines, and that has not changed," Andrin
Oswald, head of Novartis' Vaccines and Diagnostics unit, said. Last month, Intercell's partner Merck & Co (MRK.N) decided
to discontinue a major trial of a vaccine designed to protect
against serious hospital infections, adding to worries about
Intercell's pipeline's prospects. [ID:nLDE757026] The group's stock has lost over 74 percent of its value so
far this year as various disappointments have weighed on its
volatile shares. Intercell has a free float of nearly 82 percent
and is worth around $206 million. Lingelbach has said he still sees further growth of
Intercell's only marketed product, Ixiaro, a vaccine for
Japanese encephalitis, which is a mosquito-borne virus that
causes inflammation of the brain. Intercell is hoping for 60 to 70 percent sales growth this
year for the vaccine, though the product's prospects took a
knock earlier this year when Intercell had to recall batches in
Europe due to a possible loss of potency. Intercell distributes
the vaccine with Novartis. [ID:nLDE74Q0GR](Editing by Ben Hirschler)
...
Open whole article (external link)
Other Financial and Stock Market News concerning Merck & Co. Inc.
Merck & Co. Inc. Stock Summary
Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
